2023 Fiscal Year Final Research Report
Biomarkers for early diagnosis of multiple system atrophy
| Project/Area Number |
21K07455
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52020:Neurology-related
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
池内 健 新潟大学, 脳研究所, 教授 (20372469)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | 多系統萎縮症 / バイオマーカー |
|---|
| Outline of Final Research Achievements |
Multiple system atrophy (MSA) is a progressive neurodegenerative disease. The clinical diagnosis of MSA is challenging, particularly in the early stage, because of the phenotypic heterogeneity and overlapping clinical presentations. Thus, there is a need for biomarkers that can be used as a diagnostic tool for MSA.This study clarified CSF biomarker’s diagnostic performance, including α-syn, Aβ42, t-tau, p-tau181, NfL and NG2 in diagnosing MSA. Furthermore, we also investigated the correlations between these CSF biomarkers and clinical parameters and progression in MSA. We found that CSF α-syn, Aβ42, and p-tau were significantly lower, and NfL was higher in patients with MSA than in controls. Moreover, the levels of NfL can be a biomarker for predicting the progression rate of MSA. These results may have diagnostic and prognostic implications in the management of MSA.
|
| Free Research Field |
脳神経内科
|
| Academic Significance and Societal Importance of the Research Achievements |
多系統萎縮症の病態研究が進み，国内外で病態機序に即した疾患修飾薬の開発がすすめられている．疾患修飾薬の導入には，神経細胞の脱落が進んだ進行期では，薬剤の効果は限定的と考えられ，治療介入が可能な発症早期の診断が重要となってきている．多系統萎縮症は多様な臨床表現型を呈し，発症早期の診断は難しいケースが少なくないことから，早期診断に有用なバイオマーカーが求められている．また多系統萎縮症患者の症状進行速度は患者間で差が大きく，発症後の進行を予測するバイオマーカーも重要性が増している．本研究は多系統萎縮症の早期診断，進行予測に寄与しうると考えられる．
|
